Rescue Me: The Challenge Of Compassionate Use In The Social Media Era
TweetThe Development of Brincidofovir And Its Possible Use To Treat Josh Hardy
Last March 4, seven-year old Josh Hardy lay critically ill in the intensive care unit at St Jude Children’s Hospital in Memphis, Tennessee with a life-threatening adenovirus infection. His weakened immune system was unable to control the infection, a complication of a bone marrow stem cell transplant he needed as a result of treatments for several different cancers since he was 9 months old.
His physicians tried to treat the adenovirus with an anti-viral agent, Vistide (IV cidofovir), but had to stop due to dialysis-dependent renal failure. They were aware of another anti-viral in Phase 3 clinical development, brincidofovir, an oral compound chemically related to Vistide. In earlier clinical testing brincidofovir had shown the potential for enhanced antiviral potency and a more favorable safety profile.
Chimerix (where one of us, Moch, was CEO), a 55 person North Carolina-based biopharmaceutical company, had previously made brincidofovir available to more than 430 critically ill patients in an expanded access program for the treatment of serious or life-threatening DNA viral infections, including adenovirus as well as herpes viruses (such as cytomegalovirus) and polyomaviruses. This program started in 2009 as a series of individual physician-sponsored emergency INDs — investigational new drug exemptions issued in physician-certified compassionate use situations.
The program evolved via wo...
Source: Health Affairs Blog - Category: Health Management Authors: Arthur Caplan and Kenneth Moch Tags: Access All Categories Bioethics Biotech Consumers Pharma Policy Research Technology Source Type: blogs
More News: Adenoviruses | Biotechnology | Blindness | Blogging | Budgets | Cancer | Cancer & Oncology | Cancer Vaccines | Chemistry | Child Development | Children | Clinical Trials | Contracts | Cytomegalovirus | Dementia | Department of Health | Dialysis | Disability | Emergency Medicine | Environmental Health | Food and Drug Administration (FDA) | Funding | Government | Health | Health Management | Health Medicine & Bioethics Commentators | Herpes | Hospital Management | Hospitals | Insurance | Intensive Care | Investigational New Drugs | Lawsuits | Legislation | Medical Devices | Medical Ethics | Opthalmology | Oral Cancer | Pediatrics | Pharmaceuticals | Politics | Renal Failure | Science | Smallpox | Smallpox Vaccine | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants | Vaccines | Virology